Clinical Trial Update: Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects [Phase 1]

View source ↗

Summary

A Phase 1 dosage-escalation trial assessed safety and immunogenicity of the novel ChAd155-RG rabies vaccine versus RABAVERT in healthy adults; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• ChAd155-RG (ChAd155-RG)
• RABAVERT (Rabies vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Rabies, Rabies Immunisation | Phase 1 | Status: COMPLETED | Results posted: 2024-04-10